Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Zhihe Biomedical Technology

Request full access

Making imaging agents for pd-l1 and cd8+ t cells

Suzhou Shi, ChinaFounded 2015Biotech & Life Sciences

About Suzhou Zhihe Biomedical Technology

SmartNuclide Biopharma is pioneering the development of innovative nuclear medicine treatments, focusing on targeted therapies that offer new hope to patients with cancer. Established in 2015 and located in Suzhou Industrial Park, the company is committed to leveraging cutting-edge technologies to develop diagnostic and therapeutic solutions that address unmet medical needs in oncology.

SmartNuclide’s primary innovation lies in its SRC (Single-domain Radiopharmaceuticals for Cancer) technology platform, which integrates single-domain antibodies with radionuclide technology to create novel biomolecular agents. These agents are designed to target specific cancer-related biomarkers, allowing for precise imaging and treatment of various cancer types.

The company's product pipeline includes several promising candidates:

SNA001: A recombinant human thyroid-stimulating hormone (rhTSH), enhances radioiodine therapy's efficacy in differentiated thyroid cancer, reducing treatment discomfort.

SNA002: A radiolabeled imaging agent targeting PD-L1, which is crucial for the non-invasive assessment of tumor PD-L1 expression and monitoring immunotherapy efficacy.

SNA006: A CD8+ T-cell imaging agent, offering insights into the immune system's activity within the tumor microenvironment, crucial for evaluating immunotherapeutic interventions.

SNA018: Details are less specified, but like its peers, it is aimed at enhancing the diagnosis and treatment of oncological diseases.

SmartNuclide is also recognized for its contribution to the scientific community, with multiple research papers published in esteemed journals, adding valuable knowledge to the field of nuclear medicine.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Apr 2024 $14M $55M Guangzhou Jiansu Private Equity Fund · Oriza Holdings · Leading Venture Capital · Realharmony Capital ↗
SERIES B✓Equity / VC Apr 2020 $14M $56M Ruihe Investment ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Zhihe Biomedical Technology website traffic

Latest recorded traffic for Suzhou Zhihe Biomedical Technology is 330 monthly website visits, down 35.3% over the last three months. Suzhou Zhihe Biomedical Technology's team grew 0% over the past year.

Latest monthly visits330 3-month web change-35.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Zhihe Biomedical Technology in the Suzhou Shi ecosystem

Live from Dealroom

The Suzhou Zhihe Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Alphamab Oncology

Series A2 investors entered at this stage

  • Longmen Capital
  • Ruihe Investment

Series B and later5 investors entered at this stage

  • Guangzhou Jiansu Private Equity Fund
  • Oriza Holdings
  • Leading Venture Capital
  • Realharmony Capital
  • Yuzhi Capital
Employees 1 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Zhihe Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Zhihe Biomedical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.